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Abstract
Background: In resource limited settings access to laboratory monitoring of HIV treatment is limited and
therapeutic drug monitoring is generally unavailable. This study aimed to evaluate nevirapine concentrations in
saliva using low-cost thin-layer chromatography (TLC) and nevirapine concentrations in plasma and saliva using
high performance liquid chromatography (HPLC) methods; and to correlate nevirapine plasma concentrations to
HIV treatment outcomes in Ugandan patients.
Methods: Paired plasma and stimulated saliva samples were obtained from Ugandan, HIV-infected adults on
nevirapine-based ART. Nevirapine concentrations were measured using a validated HPLC method and a novel TLC
method. Plasma nevirapine concentrations <3.0 mg/L using HPLC were considered subtherapeutic. Negative/positive
predictive values of different thresholds for subtherapeutic nevirapine concentrations in saliva were determined.
Virologic testing and, if applicable, HIV drug resistance testing was performed.
Results: Median (interquartile range, IQR) age of 297 patients was 39.1 (32.8-45.2) years. Three hundred saliva
and 287 plasma samples were available for analysis. Attempts failed to determine nevirapine saliva concentrations by
TLC. Using HPLC, median (IQR) nevirapine concentrations in saliva and plasma were 3.40 (2.59-4.47) mg/L and 6.17
(4.79-7.96) mg/L, respectively. The mean (coefficient of variation,%) nevirapine saliva/plasma ratio was 0.58 (62%). A
cut-off value of 1.60 mg/L nevirapine in saliva was associated with a negative/positive predictive value of 0.99/
0.72 and a sensitivity/specificity of 87%/98% for predicting subtherapeutic nevirapine plasma concentrations, respectively.
Only 5% (15/287) of patients had subtherapeutic nevirapine plasma concentrations, of which 3 patients had viral
load results > 400 copies/mL. Patients with nevirapine concentrations in plasma <3.0 mg/L had an Odds Ratio of
3.29 (95% CI: 1.00 – 10.74) for virological failure (viral load >400 copies/mL).
Conclusions: The low-cost TLC technique for monitoring nevirapine in saliva was unsuccessful but monitoring
nevirapine saliva and plasma concentrations using HPLC was shown to be feasible in the research/specialist context
in Uganda. Further optimization and validation is required for the low-cost TLC technique.
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Background
Access to antiretroviral therapy (ART) is improving in de-
veloping countries which experience the greatest disease
burden arising from HIV infection. The successful roll-out
of ART was achieved by adopting a public health approach
to HIV care and treatment involving cost minimization
strategies, delegation of tasks from highly skilled to less
skilled health workers and simplification of the routine la-
boratory tests that are used to monitor ongoing efficacy of
ART [1,2]. Due to cost constraints, laboratory monitoring
of ART efficacy is often limited to the CD4 cell count - a
test that has low accuracy for identifying patients experien-
cing treatment failure to ART [3]. The gold standard for
treatment failure, viral load testing, is largely unavailable
because of its complexity and costs. Low-cost laboratory
tests are needed to optimize ART monitoring in develop-
ing countries.
Nevirapine, a non-nucleoside reverse transcriptase in-
hibitor, is one of the most widely used components of
first-line ART, because of its low cost, good long-term
tolerability, and high efficacy [4,5]. However, a disadvan-
tage of nevirapine is the emergence of drug resistant
virus due to its long elimination half-life and low genetic
barrier to resistance, as one single resistance mutation
can result in complete loss of virologic efficacy [6]. Not-
ably, suboptimal plasma concentrations of antiretroviral
drugs may increase the risk of treatment failure [7]. For
therapeutic drug monitoring (TDM) of nevirapine a trough
plasma concentration >3.0 mg/L is suggested [8,9]. How-
ever, nevirapine pharmacokinetics exhibit marked interpati-
ent variability that can be explained in part by genetic
differences, drug-drug interactions, pregnancy and other
(ethnic) factors [10-12].
Adherence to ART is critical for treatment success,
but routine clinical measures of adherence (e.g. patient
self-report) are subjective and can be prone to social de-
sirability bias. To date, there are no recommended la-
boratory tests to directly evaluate adherence to ART in
developing countries [13,14]. Confirmation of treatment
failure is limited by the high cost of definitive diagnostics
(e.g. HIV viral load and resistance testing). Consequently,
in resource-limited settings, it is often difficult to distin-
guish patients who are non-adherent from patients with
treatment failure arising from the emergence of drug-
resistant virus. International guidelines recommend that
patients with suspected treatment failure to nevirapine-
based ART are switched to second-line regimens being
significantly more expensive than first-line regimens
[2,15]. Thus, TDM can be used to identify non-adherent
patients and thereby prevent unnecessary switching to
more expensive ART regimens [16,17].
However, TDM can only be recommended if such
methods are accurate, robust, available and affordable in
developing countries. To this end, one African study
validated the use of a TLC technique as a low cost alter-
native to HPLC for TDM in patients using nevirapine
[18]. Nevirapine concentrations are generally measured
in blood samples, but saliva has been reported to be an
acceptable alternative matrix [19,20]. Saliva sampling is
less invasive than blood sampling and so it may be pref-
erable for certain special populations (e.g. children).
However, clinical experience is limited and therapeutic
cut-offs for nevirapine in saliva have not yet been evalu-
ated in relation to virologic failures.
This study aimed to validate nevirapine concentration
measurements in saliva samples using TLC and nevira-
pine concentrations in saliva and plasma using standard
validated HPLC method. Furthermore, we aimed to cor-
relate subtherapeutic nevirapine levels with virological
outcome of ART and HIV drug resistance development
in a cohort of Ugandan adults on (long-term) ART.
Methods
This was a cross-sectional pharmacokinetic study, which
was conducted at three clinical sites (Mbale, Fort Portal
and Kampala) of the Joint Clinical Research Centre - a
major provider of ART in Uganda. The study was de-
signed as a sub-study within a longitudinal prospective
antiretroviral monitoring study: the Pan African Studies
to Evaluate Resistance (PASER) program (http://aighd.
org/projects/paser/). Ethics approval was obtained from
the Joint Clinical Research Clinic (JCRC) Institutional
Review Board, Kampala, Uganda and the Academic
Medical Center Institutional Review Board, Amsterdam,
The Netherlands. Written informed consent was obtained
from all patients prior to participation in the study.
Participants were HIV-1 infected adults receiving nevi-
rapine as part of their ART regimen for at least 24 months.
In order to reach the target sample size of 300 patients,
additional non-PASER patients attending ART clinics at
the three study sites were recruited. The study excluded
patients with oral lesions or ulcers or serious illness re-
quiring immediate treatment or hospitalization. With a
sample size of 300 subjects and assuming a 10% rate of
sub-therapeutic values, the proportion of patients with
sub-therapeutic nevirapine concentrations in saliva and
plasma could be measured with a 95% confidence interval
of 7.4% to 12.6%.
Study patients underwent a full clinical assessment in-
cluding collection of demographic data, WHO clinical
stage and self-reported adherence in the last 3 and
30 days before sampling [21]. Routine laboratory results
including CD4 cell count, viral load and hemoglobin
were obtained from local laboratory records. Prior to
pharmacokinetic blood and saliva sampling, participants
provided information on the time of last intake of nevi-
rapine and use of any concomitant medicines over the
preceding 24 hours.
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Venous whole blood samples were obtained from
study participants and EDTA anti-coagulated plasma
specimens were stored at −80°C. Saliva samples were ob-
tained using a dental cotton roll impregnated with citric
acid (Salivette®, Sarstedt, Etten-Leur, The Netherlands).
From each patient, approximately 5 mL of saliva was iso-
lated by centrifugation of the cotton roll. Two aliquots
of each saliva sample were stored at −80°C.
Nevirapine concentrations were measured in paired
plasma and saliva samples using a validated HPLC method
at the Infectious Diseases Institute, Kampala, Uganda
(lower limit of quantification 0.05 mg/L) [18]. The accur-
acy of the HPLC assay ranged from 94 – 96% for saliva
and 94 – 99% for plasma. Individual and mean nevirapine
saliva/plasma ratios were determined. Plasma nevirapine
concentrations below 3.0 mg/L were considered sub-
therapeutic.
Nevirapine concentrations in saliva samples were also
measured at the JCRC reference laboratory in Kampala,
Uganda using an earlier described TLC technique which
reported a sensitivity of 92% and specificity of 99% when
compared to plasma concentrations determined by HPLC
[18]. For HPLC measurements, we determined the nega-
tive and positive predictive values of different thresholds
for sub-therapeutic saliva concentrations of nevirapine
for predicting nevirapine plasma concentrations above
or below 3.0 mg/L.
HIV-RNA determination and genotypic resistance test-
ing if HIV-RNA was >1000 copies/mL was performed,
as described elsewhere [22]. Drug resistance mutations
were scored according to the 2013 International AIDS
Society-USA list [23]. Subtypes were determined using
the SCUEAL HIV-1 subtyping tool [24] and additional
analysis with the REGA algorithm version 2.0 [25], if
required.
Clinical and demographic data were summarized and
were presented as median values with interquartile
ranges and numbers percentages for categorical values.
Results
A total of 297 patients were enrolled in the study: 120
(40.4%) were co-enrolled from the PASER-M cohort and
the remaining 177 (59.6%) were enrolled from antiretro-
viral clinics in the three study sites. Demographic char-
acteristics are shown in Table 1.
Two hundred and ninety seven saliva samples and 287
plasma samples were available for analysis. Median
(IQR) nevirapine concentrations in saliva and plasma
was 3.40 (2.59-4.47) mg/L and 6.17 (4.79-7.96) mg/L, re-
spectively. Corresponding mean (standard deviation)
concentrations for saliva and plasma were 6.71 (3.39)
and 3.72 (2.16) mg/L, respectively.
We found a strong positive correlation between nevi-
rapine concentrations in plasma and saliva (Spearman’s
rho, 0.886, p <0.001).
Only 15 patients (5%) had nevirapine plasma concen-
trations below 3.0 mg/L by using HPLC. The mean (co-
efficient of variation,%) nevirapine saliva-to-plasma ratio
was 0.58 (62%). A cut-off nevirapine concentration of
1.60 mg/L in saliva was associated with the highest nega-
tive and positive predicted values of 0.99 and 0.72, re-
spectively and with the highest sensitivity and specificity
of 87% and 98%, respectively for predicting nevirapine
plasma concentrations below 3.0 mg/L. Area under the
receiver operating characteristic curve was 0.924 (95%
confidence interval (CI), 0.83 - 1.00).
Table 1 Baseline characteristics of study patients
Characteristic Total (n = 297) Nevirapine plasma
conc. ≥3.0 mg/L (n = 282)
Nevirapine plasma
conc. <3.0 mg/L (n = 15)
Sex, female 201 (67.7) 192 (68.1) 9 (60.0)
Age (years) 39.1 (32.8-45.2) 39.2 (33.1-45.2) 33.3 (30.9-42.8)
Time on ART (months) 28.5 (25.8-33.5) 28.1 (25.9-32.6) 31.1 (24.4-41.2)
NRTI backbone
zidovudine 235 (79.1) 223 (79.1) 12 (80.0)
tenofovir 19 (6.4) 17 (6.0) 2 (13.3)
HIV-RNA >400 copies/mL* 21 (8.9) 18 (8.1) 3 (23.1)
30-day adherence
100% 260 (91.6) 248 (91.9) 12 (85.7)
95- < 100% 19 (6.7) 18 (6.7) 1 (7.1)
<95% 5 (1.8) 4 (1.5) 1 (7.1)
3-day adherence (any pills missed) 9 (3.3) 6 (2.3) 3 (20.0)
CD4 cell count (cells/mm3) 363 (265–509) 385 (269.5-511) 299 (211–354)
Baseline characteristics stratified by patients with therapeutic (≥3.0 mg/l) or subtherapeutic (<3.0 mg/L) nevirapine plasma concentrations.
Values in brackets are n (%) for categorical variables and median (interquartile range, IQR) for continuous variables. * HIV-RNA results from 235 patients
were available.
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Despite multiple attempts, it was not possible to deter-
mine nevirapine concentrations in saliva samples following
the TLC technique used by L’homme et al. in Tanzania
[18]. There were no nevirapine spots detectable on the
TLC plates or spots from the validated by HPLC nevira-
pine reference solutions. Structured trouble-shooting by
following a step-by-step procedure to locate the error in
the assay was unsuccessful. Therefore, analysis using the
TLC method was terminated from the current study.
As stated, 5% (15/287) of study patients had sub-
therapeutic nevirapine plasma concentrations. Thirteen
of these patients had a viral load result available and 3
patients (23%) had a viral load result of > 400 copies/mL,
see Table 2. Patients with sub-therapeutic nevirapine
concentrations in plasma (<3.0 mg/L) had an Odds Ratio
(OR) of 3.29 (95% CI: 1.00 – 10.74) for virological failure
(viral load >400 copies/mL) than patients with adequate
nevirapine plasma concentrations. Among the 21 pa-
tients with viral load >400 copies/mL, genotypic resist-
ance mutations were detected in 14 out of 15 patients
with available genotyping results. Only 2 of these pa-
tients had sub-therapeutic nevirapine concentrations in
plasma (Table 2). The most common nevirapine-associated
HIV drug resistance mutations were K103N, Y181C and
G190A.
Discussion
Using HPLC, monitoring nevirapine concentrations in
saliva and plasma samples was shown to be feasible and
potentially useful in a specialist and research facility in
Uganda. In contrast, the low-cost TLC technique did
not appear robust. For unknown reasons, in Uganda, at-
tempts to set-up the TLC assays for nevirapine in saliva
failed, while in neighbouring Tanzania the same method
was successful and validated [18]. In other studies, the
TLC technique was successful for the semi-quantitative
determination of nevirapine in saliva and other matrices
[26-29]. In these studies, the low-cost TLC method was
reported as sensitive, specific, robust, and able to detect
sub-therapeutic concentrations of the drug, and the re-
sults compared well with HPLC.
However, the TLC method suffers from two key short-
comings: the reliance on the laboratory technicians’ vis-
ual acuity for estimation of drug content, and the lab
technicians’ skills for manually applying sample solution
spots on the chromatographic plate with adequate preci-
sion [30]. In our study, the laboratory technicians were
well trained for this procedure and no definite cause was
established for the failure of the TLC technique in the
present study. Hypotheses to explain the failure of the
nevirapine TLC assay include the influence of local
temperature and humidity on the TLC plates that were
stored at the site approximately 18 months during the
conduct of the study.
As determined by HPLC, nevirapine concentrations in
plasma were within the expected range and the calcu-
lated nevirapine saliva-to-plasma ratio of 0.58 was con-
sistent with previous reports [18,21]. Factors influencing
the penetration of drugs into saliva include molecular
size, plasma protein binding, saliva flow rates and lipid
solubility of drugs [31]. Indeed, approximately 60% of
nevirapine in plasma is bound to plasma proteins and
the free fraction of nevirapine could drive significant
quantities of nevirapine into saliva and other matrices.
For instance, a cerebrospinal fluid to plasma ratio of
0.45 has been reported for nevirapine [32].
We determined the cut-off value for nevirapine in saliva
was 1.60 mg/L with a high positive and negative predictive
value for identifying a patient with a sub-therapeutic nevi-
rapine concentration in plasma. Previously, cut-offs of
1.5 mg/L and 1.75 mg/L have been used [13,29].
Although patients with sub-therapeutic concentrations
of nevirapine had increased odds of having a viral load >
400 copies/mL, the magnitude of odds ratio was small
and the lower bounds of the 95% confidence interval in-
cluded the no-effect boundary of 1. In contrast, an obser-
vational cohort analysis in Netherlands which followed up
189 patients and obtained untimed nevirapine plasma
samples at approximately 6 months after commencing
nevirapine-based ART, found that subtherapeutic nevi-
rapine concentrations were associated with increased
risk of subsequent virologic failure (relative risk 5.0
95% CI, 1.8 – 13.7).
Due to the cross-sectional nature of the current study
that was conducted at 2 years after commencement of
ART, the study population could be prone to selection
bias arising from drop-outs within the first two years of
ART. It is conceivable that prior to the second year of
ART, some patients with sub-therapeutic concentrations
could experience treatment failure and switch therapy,
Table 2 Characteristics of patients with virological failure (HIV-RNA >400 copies/mL) and nevirapine plasma
concentrations below 3 mg/L
Patient ID sex Age (years) Nevirapine plasma conc. (mg/L) 30-day adherence Viral load (copies/mL) NNRTI DRMs NRTI DRMs
MBA029 female 30 0.44 100% 40768 K103N M184IMV
JCR089 female 32 0.21 95- < 100% 966 ND ND
JCR086 male 48 0.03 100% 696298 G190A None
NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, DRM = drug resistance mutation (as identified Stanford
Genotypic Resistance Interpretation Algorithm), ND = no data available.
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experience opportunistic infections that would preclude
them from study participation or die. Importantly, such
a scenario would likely bias towards the null an associ-
ation between sub-therapeutic concentrations and viral
loads >400 copies/mL. In the current study, the propor-
tion of patients with sub-therapeutic nevirapine concen-
trations was 5%, which was lower than the estimate of
10% which was utilized in sample size calculations. In
two Tanzanian studies, sub-therapeutic nevirapine con-
centrations in plasma were observed in 9% [18] and
13.2% [29] of samples. Consequently, a Type II error in
the current study cannot be ruled out.
An important study limitation is that adherence was ob-
tained by patient self-report and it is possible that this was
overestimated, particularly among subjects with negligible
nevirapine concentrations. Furthermore, the study was
cross-sectional in design and as such temporal variation in
adherence over time was not captured. This limitation
could have resulted in the poor correlation of adherence
to virologic failure as it is possible that previously non-
adherent patients who develop virologic failure could sub-
sequently improve on their adherence. Moreover, this
study design cannot be used to determine the effectiveness
of TDM. Instead, prospective, randomized studies in re-
source limited settings should be considered to address
this question.
Due to financial and technical constraints monitoring
conventional viral load and HIV-drug resistance testing
is infrequently performed in resource-limited settings.
However, recent technological advances are likely to en-
able lower test costs, to simplify sample storage using
dried blood spots and to utilize equipment that require
less technical expertise [33]. These novel tests are cur-
rently being piloted at various locations in sub-Saharan
Africa. In developing countries, non-invasive saliva sam-
pling, in combination with the use of a robust and low
cost assay could complement viral load testing and po-
tentially become an attractive alternative to resistance
testing among patients who are suspected to be primar-
ily non-adherent. Our findings suggest that the low-cost
TLC technique may not be sufficiently robust for wide-
spread implementation. In contrast, the HPLC assay was
shown to be robust in a resource-limited setting. Fur-
thermore, the availability of HPLC in countries like
Uganda would diminish the need for TLC methodology.
However, when compared to virologic monitoring, it is
unlikely that the HPLC monitoring would be cost-
effective in these settings given the high set-up costs and
the limited clinical role of results from pharmacologic
tests.
Conclusions
In conclusion, while the low-cost TLC technique for mon-
itoring nevirapine in saliva was unsuccessful, monitoring
nevirapine saliva and plasma concentrations using HPLC
was feasible in a specialist and research centre in Uganda.
While HPLC technology may not be adaptable for wide-
spread use in resource-limited settings, investment in this
technology may be justified in specialist centres that pro-
vide support to large ART clinics or multiple clinical sites.
Further optimization and validation is required for the
low cost TLC technique.
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